NCT07223411Recruiting
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 30 Oct 2025
- Start date
- 19 Nov 2025
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- John Kirkwood
- Diseases
- Melanoma
- NCT number
- NCT07223411
What you commit to
- Study type: Observational
- Planned participants: 20
- From 19 Nov 2025 to the primary completion date, 1 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study.
- \-
Who the study is looking for
- Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.
- Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:
- 3 additional tumor biopsies
- 3 additional blood draws
- Participants must have biopsiable non-target disease amenable to at least 3 biopsies.
- Must have the ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UPMC Hillman Cancer Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.